featured
Ramucirumab With Osimertinib in Advanced T790M-Positive EGFR-Mutant NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination With Osimertinib in Advanced T790M-Positive EGFR-Mutant Non–Small Cell Lung Cancer
Clin. Cancer Res 2021 Feb 15;27(4)992-1002, HA Yu, LG Paz-Ares, JC Yang, KH Lee, P Garrido, K Park, JH Kim, DH Lee, H Mao, SR Wijayawardana, L Gao, RR Hozak, BH Chao, D PlanchardFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.